Plasma and intrapulmonary pharmacokinetics of cefepime and taniborbactam in healthy adult participants.

ABSTRACT: Cefepime-taniborbactam is being developed for the treatment of serious multidrug-resistant (MDR) Gram-negative bacterial infections. This study determined and compared plasma and epithelial lining fluid (ELF) concentrations of cefepime and taniborbactam in 30 healthy adult participants. The dosing regimen was 2 g cefepime/0.5 g taniborbactam administered as a 4 h intravenous infusion every 8 h for a total of six doses. Mean plasma and ELF concentration values with the four aspirates at each bronchoalveolar lavage (BAL) sampling time (1, 3, 4.25, 5, 6, and 8 h) were used to estimate the area under the concentration-time curve (AUC_0-8). The mean AUC_0-8 values of unbound plasma concentrations of cefepime and taniborbactam were 262.2 and 84.77 µg·h/mL, respectively. The d

SUBMITTER: Rodvold KA 

PROVIDER: S-EPMC12217482 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature